10-Q: Select Medical Holdings Reports Mixed Q2 Results Amidst Concentra Spin-Off

Select Medical Holdings Corporation reported a slight decrease in income from operations despite a revenue increase in its second quarter, while also completing the initial public offering of its Concentra subsidiary.

Summary

• Select Medical Holdings Corporation reported a revenue of $1.76 billion for the second quarter of 2024, a 5.1% increase compared to $1.67 billion in the same period last year.
• Income from operations slightly decreased to $157.8 million, down from $159.2 million in the second quarter of 2023.
• Adjusted EBITDA for the quarter was $226.3 million, a 3.1% increase from $219.5 million in the prior year, with a margin of 12.9%.
• The company's net income was $94.8 million, compared to $91.9 million in the second quarter of 2023.
• For the first six months of 2024, revenue reached $3.55 billion, a 6.3% increase year-over-year, and net income was $211.9 million, compared to $177.1 million in the same period last year.
• Select Medical completed the initial public offering of its Concentra subsidiary on July 26, 2024, raising $528.8 million in gross proceeds.
• The company used the proceeds from the Concentra IPO and debt financing to repay $1.9 billion of its credit facilities.
• Select Medical still owns 82.23% of Concentra's outstanding shares and will consolidate its financial results until a planned distribution of the remaining equity interest to its stockholders within 12 months.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While revenue and Adjusted EBITDA increased, there are concerns about declining income from operations, decreased cash flow, and challenges in the outpatient rehabilitation segment. The successful Concentra IPO is a positive development, but the company faces several risks and operational challenges.

Positives

• Revenue increased across most segments, particularly in critical illness recovery and rehabilitation hospitals.
• Adjusted EBITDA showed overall growth, indicating improved operational efficiency.
• The successful Concentra IPO provides a significant cash infusion and allows for debt reduction.
• The company's critical illness recovery hospital segment saw a 9.7% increase in Adjusted EBITDA.
• The rehabilitation hospital segment experienced a 13.3% increase in Adjusted EBITDA.
• The company has reduced its reliance on contract labor, leading to lower costs in the critical illness recovery hospital segment.

Negatives

• Income from operations slightly decreased year-over-year.
• The outpatient rehabilitation segment experienced a decrease in Adjusted EBITDA.
• General and administrative expenses increased as a percentage of revenue.
• The company experienced a decrease in equity in earnings of unconsolidated subsidiaries.
• Cash flow from operations decreased due to an increase in accounts receivable, partly due to the Change Healthcare cybersecurity incident.

Risks

• Changes in government reimbursement policies could reduce revenue and profitability.
• Adverse economic conditions, including inflation, could increase labor and operating costs.
• Shortages of qualified healthcare professionals could limit the company's ability to staff facilities.
• Public health threats, such as pandemics, could negatively impact patient volumes and revenues.
• Failure to maintain Medicare certifications could cause revenue and profitability to decline.
• Government investigations or assertions of regulatory violations could result in sanctions and increased costs.
• Acquisitions or joint ventures may prove difficult or unsuccessful.
• Private third-party payors may adopt payment policies that could limit future revenue and profitability.
• Loss of key management personnel could disrupt operations.
• Security breaches of information technology systems could lead to legal and reputational harm.
• The company is subject to interest rate risk on its variable rate debt, which could increase interest expense.

Future Outlook

Select Medical intends to distribute its remaining equity interest in Concentra to its stockholders within twelve months of the IPO. The company believes its internally generated cash flows and borrowing capacity will allow it to finance operations in both the short and long term. The company may pursue opportunities to develop new joint ventures, open new clinics, and grow through acquisitions.

Management Comments

• Management uses Adjusted EBITDA to evaluate financial performance and determine resource allocation for each of its segments.
• Management believes that the presentation of Adjusted EBITDA is important to investors because it is commonly used as an analytical indicator of performance by investors within the healthcare industry.

Industry Context

The healthcare industry is facing challenges such as rising labor costs, regulatory changes, and cybersecurity threats. Select Medical's performance reflects these broader trends, with increased revenue offset by higher expenses and the need to adapt to new payment models. The spin-off of Concentra is a strategic move to focus on core operations and potentially unlock shareholder value.

Comparison to Industry Standards

• Select Medical's revenue growth in its critical illness recovery and rehabilitation hospital segments is in line with industry trends, as these sectors are experiencing increased demand due to an aging population and complex medical needs.
• The decrease in Adjusted EBITDA in the outpatient rehabilitation segment is a concern, as many companies in this sector are facing similar challenges with rising labor costs and reimbursement pressures.
• The successful IPO of Concentra is a significant event, as it allows Select Medical to reduce debt and focus on its core operations, similar to other healthcare companies that have divested non-core assets to improve financial performance.
• The company's occupancy rates in its critical illness recovery and rehabilitation hospitals are comparable to industry averages, indicating efficient utilization of resources.
• The company's days sales outstanding (DSO) of 56 days is higher than some of its peers, indicating a need to improve collection processes, especially in light of the Change Healthcare cybersecurity incident.

Legal Proceedings

• The company is involved in various legal actions, proceedings, and claims, including a qui tam lawsuit related to billing for respiratory therapy services at SSH-Oklahoma City.
• The company is under investigation by the U.S. Department of Justice regarding billing for physical therapy services.
• Concentra received a subpoena from the California Department of Insurance relating to an investigation under the California Insurance Frauds Prevention Act.
• The company is facing six putative class action lawsuits related to a data breach at Perry Johnson & Associates, Inc.

Stakeholder Impact

• Shareholders will benefit from the Concentra IPO and the planned distribution of remaining equity.
• Employees may be affected by changes in staffing and operational adjustments.
• Customers (patients) may experience changes in service delivery due to operational adjustments and regulatory changes.
• Suppliers may be impacted by the company's efforts to manage costs and improve efficiency.
• Creditors may be impacted by the company's debt reduction efforts and changes in its capital structure.

Next Steps

• Select Medical intends to distribute its remaining equity interest in Concentra to its stockholders within twelve months of the IPO.
• The company will continue to monitor and address the impact of the Change Healthcare cybersecurity incident on its billing and collections processes.
• The company will continue to evaluate opportunities for growth through joint ventures, new clinic openings, and acquisitions.

Key Dates

Keywords

Select Medical, Concentra, healthcare, hospitals, rehabilitation, outpatient, occupational health, EBITDA, revenue, IPO, Medicare, financial results